Skip to main content
GIPResearch.com · Patent and Technology Research

Rigel Pharmaceuticals, Inc. Received a Patent for AXL Inhibitors

Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on…

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Rigel Pharmaceuticals, Inc. Received a Patent for AXL Inhibitors
Research and original publication material

Rigel Pharmaceuticals, Inc. Received a Patent for AXL Inhibitors — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer. Rigel Pharmaceuticals, Inc. filed patent application numbered 4864/DELNP/2009 that is titled N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS. This patent application has been granted as Patent Number 307195. The invention covers chemical compounds. N3 -Heteroaryl substituted triazoles and N5 -heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the Claim(s) (1-25) are statutorily non-patentable. Further, the present compounds do not differ significantly in properties with regard to efficacy with respect to the known compounds. Thus in the absence of the same it thus appears to be new use of known substance.  As a response, applicant proved using legal arguments under the provisions of law. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to Rigel Pharmaceuticals, Inc. Received a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-29. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights